Thursday's Health Winners & Losers
Cubist Pharmaceuticals (CBST) shares sank Thursday after the stock was downgraded by research firm JMP Securities to market outperform from buy, citing a lack of near-term catalysts.
Biotech analyst Adam Cutler says the stock is cheap, however, and that "sales trends have been healthy, and there should be plenty of growth left." Cutler lowered his price target on the stock to $24 from $28. Shares fell 3.2% to $17.62.
Shares of Quest Diagnostics (DGX) lost 1.2% to $50.46 after the lab specialist guided lower for 2007.
The diagnostic test outfit earned $151 million, or 77 cents a share, in the fourth quarter, above analysts' estimates of 74 cents a share. Revenue grew 8.5% to $1.55 billion. Analysts expected revenue of $1.57 billion. For 2007, the company expects earnings of between $2.70 and $3 a share on $6 billion to $6.2 billion in revenue. Analysts were expecting earnings of $3.21 a share on sales of $6.4 billion for the year.St. Jude Medical's (STJ) shares rose 4.3% to $41.37 Thursday after the medical device maker reported an increase in fourth-quarter earnings and issued guidance for growth in 2007. The company earned $155 million, or 42 cents a share, including a retroactive benefit of approximately 3 cents a share related to a research and development tax credit for the first nine months of 2006. Analysts were expecting the company to earn 39 cents a share. Sales were $864 million, up more than 9% from the fourth quarter of 2005 and exceeding analysts' estimates of $852.35 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV